Bär & Karrer Advises Teva in the Issuance of CHF 1 Billion Notes

Teva Pharmaceutical Finance Netherlands IV B.V. successfully placed the aggregated amount of CHF 1 billion of notes in connection with the pending acquisition of Actavis Generics, consisting of the following tranches: CHF 300 million 0.125% fixed rate notes due 2018, CHF 350 million 0.500% fixed rate senior notes due 2022 and CHF 350 million 1.000% fixed rate senior notes due 2025. The notes have been listed on the SIX Swiss Exchange and are guaranteed by Teva Pharmaceutical Industries Limited. Headquartered in Israel, Teva is a leading global pharmaceutical company and world's largest generic medicines producer. BNP Paribas (Suisse) SA, Barclays Bank PLC, Credit Suisse AG, HSBC Bank plc, Merrill Lynch International, Mizuho International plc, Citigroup Global Markets Limited, Morgan Stanley & Co. International plc, RBC Europe Limited and SMBC Nikko Capital Markets Limited act as joint lead managers.

Bär & Karrer has acted as Swiss legal counsel to Teva in connection with the issuance and placement of the notes. Willkie Farr & Gallagher LLP acted as international counsel to Teva. The Bär & Karrer team comprised Eric Stupp, Martin Peyer and Annette Weber (Capital Markets) as well as Daniel Lehmann (Tax).